Cargando…

Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits

Mammographic screening before age 50 years is less effective than at older ages and the associated radiation risks are higher. We estimated how many breast cancer deaths could be caused and how many could be prevented by a decade of annual two-view mammographic screening starting at ages 20, 30 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Berrington de González, A, Reeves, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361593/
https://www.ncbi.nlm.nih.gov/pubmed/16136033
http://dx.doi.org/10.1038/sj.bjc.6602683
_version_ 1782153251349594112
author Berrington de González, A
Reeves, G
author_facet Berrington de González, A
Reeves, G
author_sort Berrington de González, A
collection PubMed
description Mammographic screening before age 50 years is less effective than at older ages and the associated radiation risks are higher. We estimated how many breast cancer deaths could be caused and how many could be prevented by a decade of annual two-view mammographic screening starting at ages 20, 30 and 40 years, respectively, in the UK; for all women, and for women with first-degree relatives affected with breast cancer. We extrapolated from a radiation risk model to estimate the number of radiation-induced breast cancer deaths, and used results from randomised trials, which suggest a reduction in breast cancer mortality of 10–20% in women invited to screening before age 50 years, to estimate the number of deaths that could be prevented. The net change in breast cancer deaths was defined as the number of radiation-induced deaths minus the number of prevented deaths. For all women, assuming a reduction in mortality from screening of 20%, a decade of annual screening was estimated to induce more deaths than it prevents if started at age 20 years and at age 30 years (net increase=0.86 and 0.37 breast cancer deaths, respectively, per 1000 women screened). The corresponding estimate for screening starting at age 40 years was a net decrease of 0.46 deaths/1000 women screened and a zero net change assuming a 10% mortality reduction. Results for women with first-degree relatives with breast cancer were generally in the same direction but, because their background incidence rates are higher, the net increases or decreases were greater. In conclusion, our estimates suggest that a decade of annual two-view mammographic screening before age 40 years would result in a net increase in breast cancer deaths, and that starting at age 40 years could result in a material net decrease only if breast cancer mortality is reduced by about 20% or more in women screened. Although these calculations were based on a number of uncertain parameters, in general, the conclusions were not altered when these parameters were varied within a feasible range.
format Text
id pubmed-2361593
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23615932009-09-10 Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits Berrington de González, A Reeves, G Br J Cancer Epidemiology Mammographic screening before age 50 years is less effective than at older ages and the associated radiation risks are higher. We estimated how many breast cancer deaths could be caused and how many could be prevented by a decade of annual two-view mammographic screening starting at ages 20, 30 and 40 years, respectively, in the UK; for all women, and for women with first-degree relatives affected with breast cancer. We extrapolated from a radiation risk model to estimate the number of radiation-induced breast cancer deaths, and used results from randomised trials, which suggest a reduction in breast cancer mortality of 10–20% in women invited to screening before age 50 years, to estimate the number of deaths that could be prevented. The net change in breast cancer deaths was defined as the number of radiation-induced deaths minus the number of prevented deaths. For all women, assuming a reduction in mortality from screening of 20%, a decade of annual screening was estimated to induce more deaths than it prevents if started at age 20 years and at age 30 years (net increase=0.86 and 0.37 breast cancer deaths, respectively, per 1000 women screened). The corresponding estimate for screening starting at age 40 years was a net decrease of 0.46 deaths/1000 women screened and a zero net change assuming a 10% mortality reduction. Results for women with first-degree relatives with breast cancer were generally in the same direction but, because their background incidence rates are higher, the net increases or decreases were greater. In conclusion, our estimates suggest that a decade of annual two-view mammographic screening before age 40 years would result in a net increase in breast cancer deaths, and that starting at age 40 years could result in a material net decrease only if breast cancer mortality is reduced by about 20% or more in women screened. Although these calculations were based on a number of uncertain parameters, in general, the conclusions were not altered when these parameters were varied within a feasible range. Nature Publishing Group 2005-09-05 2005-09-05 /pmc/articles/PMC2361593/ /pubmed/16136033 http://dx.doi.org/10.1038/sj.bjc.6602683 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Epidemiology
Berrington de González, A
Reeves, G
Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits
title Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits
title_full Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits
title_fullStr Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits
title_full_unstemmed Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits
title_short Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits
title_sort mammographic screening before age 50 years in the uk: comparison of the radiation risks with the mortality benefits
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361593/
https://www.ncbi.nlm.nih.gov/pubmed/16136033
http://dx.doi.org/10.1038/sj.bjc.6602683
work_keys_str_mv AT berringtondegonzaleza mammographicscreeningbeforeage50yearsintheukcomparisonoftheradiationriskswiththemortalitybenefits
AT reevesg mammographicscreeningbeforeage50yearsintheukcomparisonoftheradiationriskswiththemortalitybenefits